March 16 2017 Issue

The AARS online Hot Topics Newsletter is an exclusive AARS member benefit!

This is a semi-monthly compilation of peer-review literature and online updates in acne and rosacea covering industry press, new medical research and what patients and your peers are talking about in patient counseling tips.

Access Hot Topics Newsletter

You don't need to spend countless hours perusing your typical online sources when you have this! Stay informed today by becoming an AARS member and receiving the Hot Topics!

Industry News

  • Though unexpected, the most common dermatologic diagnosis at a homeless shelter clinic was acne, with approximately one in five patients presenting with the condition. This finding of a retrospective chart review was reported at the 2017 American Academy of Dermatology Annual Meeting, from March 3 – 7.
  • Cutanea Life Sciences, Inc. (CLS) introduced Aktipak (erythromycin and benzoyl peroxide) Gel, 3%/5%, a combination therapy indicated for the topical treatment of acne vulgaris. Aktipak is a portable, freshly mixed, patient-blended therapy that offers a flexible and convenient treatment option for active, "on-the-go" acne patients, according to the company.

New Medical Research

  • A study aimed at the identification and characterization of key players in Acne inversa (AI)/Hidradenitis suppurativa pathogenesis found that lipocalin (LCN)-2 might serve as a blood biomarker for objective assessment of inflammatory activity in AI.
  • Data from a study to clinically characterize premenstrual acne flare-up in adult women and investigate the effect of a dermocosmetic treatment showed a significant increase in the number of papules during premenstrual acne flare-ups in adult women. The use of a dermocosmetic may be of benefit in partially reducing this premenstrual inflammatory flare-up.
  • A new study is the first report on the safe and effective use of special silk textiles (Dermasilk) in the management of acne vulgaris papulopustulosa corporis.
  • Results of a new study suggest that ivermectin can prevent the inflammatory effects of rosacea triggered by abnormal LL-37 processing, through the inhibition of KLK5 gene expression in the epidermis.
  • A case report on a 34-year-old male with facial erythema and desquamation accompanied by Demodex tails and Demodex follicular openings shows that dermoscopy is a potential new option for a real-time validation of Demodex infestation and a useful tool for monitoring treatment.

Clinical Reviews

  • A new review article explores the effective use of cosmeceuticals in the treatment of rosacea to enhance pharmaceutical outcomes and meet patient expectations in a more satisfactory manner.
  • A new article outlines a rationale for rosacea treatment options, highlights an evidence-based approach with approved treatments, and considers novel developments and off-license therapy available.
  • The emergence of ivermectin as a key therapy for rosacea has refocused interest in the role of Demodex mites in the pathogenesis of this skin disease and the ability of Demodex to modulate the host immune system, as revisited in a new article.
  • In spite of extensive gynecologic experience in the use of combined oral contraceptives for acne, evidence based on dermatologic observation should be intensified, according to a recently published review.
  • Therapeutic approaches to reducing atrophic acne scarring are discussed in a new article.
  • According to a recently published review, acne scarring has been best treated with lasers, including nonablative infrared lasers, fractional nonablative and ablative laser resurfacing, and most recently needle-based radiofrequency devices.
  • A new article explores drug-induced acne (DIA), and states the diagnosis of DIA is made by a detailed history with a record of drug onset, dosage regimen and therapy duration, absence of additional triggering factors, and clinical relationship between the introduction of the drug and the onset of an acne-like eruption.
  • A new review describes more objective methods for assessing the severity of acne vulgaris, including photography, fluorescence photography, polarized light photography, video microscopy, and multispectral imaging. Such techniques have limitations such as high cost, complex and sophisticated apparatus, and a sometimes time-consuming imaging process, as discussed in the review.
  • Although acne is usually straightforward to diagnose and treat, some patients have difficult or rare forms of acne. These difficult and rare forms of acne are reviewed in a recently published article.
  • A new review supports photodynamic therapy (PDT) as an efficacious treatment for acne and a good adjunctive treatment for mild to severe acne, especially in patients who have not responded to topical therapy and oral antibacterials, and are not great candidates for isotretinoin.
  • A recent article provides a systematic evaluation of the scientific evidence of the efficacy of oral antibiotics for acne.
  • In a new review, investigators aim to provide an overview of acne and acneiform eruptions that can arise in the immunosuppressed host.
  • An analysis of the prevalence and risk factors of acne scarring suggests it is vital for clinicians who manage individuals with acne to institute effective therapy as early as possible, since treatment delay is a key modifiable risk factor for scarring.
  • A new article reviews the selected papers where authors present the results of their studies on different regimens with the use of isotretinoin in low doses in patients with acne, evaluate their efficacy, patient satisfaction, frequency of adverse effects, recurrences and also treatment costs.

Patient Counseling / Communication

  • Leading dermatologists offered their recommendations on the top OTC adult acne products to improve patient care and outcomes.
  • Data from a recent study suggest that the majority of patients with hidradenitis suppurativa (HS) experience prodromal symptoms, heralding a flare of their HS. The findings may give rise to important new treatment approaches for the management of HS.